WVE

Bullish

WVE: Advancing siRNA and RNA editing therapies with strong clinical data and regulatory momentum

Wave Life Sciences (WVE) is making significant progress in its siRNA and RNA editing platforms, demonstrating promising clinical data for obesity and ...

TradingView 2 days ago 0

Neutral

Wave Life Sciences (Nasdaq: WVE) details 2025 milestones, cash and executive pay

Wave Life Sciences (WVE) filed an amendment to its 10-K report, providing detailed information on its directors, executive officers, corporate governa...

Stock Titan 3 weeks ago 0

Bullish

Does Strong Q1 2026 Beat and Narrower Loss Reshape The Bull Case For Wave Life Sciences (WVE)?

Wave Life Sciences (WVE) reported stronger-than-expected Q1 2026 results, with revenue up to US$38.25 million and a narrower net loss of US$26.09 mill...

Simply Wall Street 3 weeks ago 0